Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA
Leo Pharma, a small, century-old Danish drugmaker, has spent the past few years tailing Sanofi on their franchise drug Dupixent, betting that an antibody they licensed from AstraZeneca coupled with a few decades of expertise in dermatology could compete with one of Big Pharma’s biggest drugs. They got a huge boost in that regard in December, with positive Phase III results in atopic dermatitis, and last week, when they announced the FDA had accepted their BLA for the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.